Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335839 | 0.83 | CYP2D6 (0.37) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL4343020 | 0.83 | CYP2D6 (0.37) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL5189416 | 0.80 | CYP2D6 (0.40) | CTSKCTSSCYP2D6CA1CA2 | |
| SCHEMBL30485492 | 0.79 | CYP2D6 (0.39) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL26924263 | 0.79 | CYP2D6 (0.42) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL26924266 | 0.79 | CYP2D6 (0.42) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL23551450 | 0.77 | CYP2D6 (0.38) | CTSKCYP2D6CA1CA2CA12 | |
| SCHEMBL21209086 | 0.76 | MEN1 (0.47) | CTSKCTSSCA1CA2CA12 | |
| SCHEMBL1434048 | 0.76 | CTSK (0.40) | CTSKCTSSCYP2D6CA1CA2 | |
| SCHEMBL6239277 | 0.76 | CYP2D6 (0.37) | CTSKCTSSCYP2D6CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580852-B2 | 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | PLA2G2E, PLA2G4A, PLAA | CTSK 2760/4885CTSS 2394/4885TSHR 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.